CA2623210A1 - Ppar-gamma agonists for improvement of cognitive function in apoe4 negative patients - Google Patents

Ppar-gamma agonists for improvement of cognitive function in apoe4 negative patients Download PDF

Info

Publication number
CA2623210A1
CA2623210A1 CA002623210A CA2623210A CA2623210A1 CA 2623210 A1 CA2623210 A1 CA 2623210A1 CA 002623210 A CA002623210 A CA 002623210A CA 2623210 A CA2623210 A CA 2623210A CA 2623210 A1 CA2623210 A1 CA 2623210A1
Authority
CA
Canada
Prior art keywords
ppar
subject
gamma agonist
apoe4
kit according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002623210A
Other languages
English (en)
French (fr)
Inventor
Allen D. Roses
Ann M. Saunders
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Cork Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37876831&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2623210(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2623210A1 publication Critical patent/CA2623210A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002623210A 2005-09-22 2006-09-20 Ppar-gamma agonists for improvement of cognitive function in apoe4 negative patients Abandoned CA2623210A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US71935305P 2005-09-22 2005-09-22
US60/719,353 2005-09-22
US72737705P 2005-10-17 2005-10-17
US60/727,377 2005-10-17
PCT/US2006/036603 WO2007038115A2 (en) 2005-09-22 2006-09-20 Ppar-gamma agonists for improvement of cognitive function in apoe4 negative patients

Publications (1)

Publication Number Publication Date
CA2623210A1 true CA2623210A1 (en) 2007-04-05

Family

ID=37876831

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002623210A Abandoned CA2623210A1 (en) 2005-09-22 2006-09-20 Ppar-gamma agonists for improvement of cognitive function in apoe4 negative patients
CA002623204A Abandoned CA2623204A1 (en) 2005-09-22 2006-09-20 Combination of rosiglitazone and donepezil for improvement of cognitive function

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA002623204A Abandoned CA2623204A1 (en) 2005-09-22 2006-09-20 Combination of rosiglitazone and donepezil for improvement of cognitive function

Country Status (16)

Country Link
US (2) US20080262047A1 (cg-RX-API-DMAC10.html)
EP (2) EP1926488A2 (cg-RX-API-DMAC10.html)
JP (2) JP2009508960A (cg-RX-API-DMAC10.html)
KR (2) KR20080058413A (cg-RX-API-DMAC10.html)
AR (2) AR056527A1 (cg-RX-API-DMAC10.html)
AU (2) AU2006295007A1 (cg-RX-API-DMAC10.html)
BR (2) BRPI0616192A2 (cg-RX-API-DMAC10.html)
CA (2) CA2623210A1 (cg-RX-API-DMAC10.html)
CR (2) CR9848A (cg-RX-API-DMAC10.html)
EA (2) EA200800879A1 (cg-RX-API-DMAC10.html)
IL (2) IL190217A0 (cg-RX-API-DMAC10.html)
MA (2) MA29872B1 (cg-RX-API-DMAC10.html)
NO (2) NO20081843L (cg-RX-API-DMAC10.html)
PE (2) PE20070976A1 (cg-RX-API-DMAC10.html)
TW (2) TW200803896A (cg-RX-API-DMAC10.html)
WO (2) WO2007038112A2 (cg-RX-API-DMAC10.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2066355A2 (en) * 2006-09-19 2009-06-10 Braincells, Inc. Combination comprising a peroxisome proliferator activated receptor agent and a second neurogenic agent for treating a nervous system disorder, increasing neurodifferentiation and increasing neurogenesis
IL187159A0 (en) 2007-07-03 2009-02-11 Gur Megiddo Use of metadoxine in relief of alcohol intoxication
WO2009043593A1 (en) * 2007-10-05 2009-04-09 Merz Pharma Gmbh & Co. Kgaa Combination therapy using memantine and glitazones
EP2085120A1 (en) * 2008-02-01 2009-08-05 Merz Pharma GmbH & Co. KGaA The use of substances for the treatment of central or peripheral insulin receptor impairment and insulin resistance
KR20160127181A (ko) 2008-08-12 2016-11-02 진판델 파마슈티컬스 인코포레이티드 질환 위험 인자의 식별 방법
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
US20100152249A1 (en) * 2008-12-11 2010-06-17 Board Of Trustees Of The Leland Stanford Junior University Compositons and method for treatment of mood and cognitive impairments
NZ597319A (en) * 2009-06-25 2014-06-27 Alcobra Ltd A method for the treatment, alleviation of symptoms of, relieving, improving and preventing a cognitive disease, disorder or condition
US20100178307A1 (en) * 2010-01-13 2010-07-15 Jianye Wen Transdermal anti-dementia active agent formulations and methods for using the same
WO2012053016A1 (en) * 2010-10-22 2012-04-26 Cadila Healthcare Limited Sustained release pharmaceutical compositions of donepezil
CN107362165A (zh) 2011-01-10 2017-11-21 金帆德尔制药股份有限公司 用于治疗阿尔茨海默病的方法和药物产品
BR112013017444A2 (pt) * 2011-01-10 2016-09-27 Zinfandel Pharmaceuticals Inc método de determinar o risco para o desenvolvimento da doença de alzheimer em um indivíduo, de tratar um indivíduo para a doença de alzheimer e de determinar um risco para desenvolver a doença de alzheimer em um paciente
AP2014007645A0 (en) 2011-10-21 2014-05-31 Takeda Pharmaceutical Sustained-release preparation
CA2853100A1 (en) * 2011-10-24 2013-05-02 Intellect Neurosciences, Inc. Compositions and methods for treatment of proteinopathies
US20160113913A1 (en) * 2013-04-19 2016-04-28 Takeda Pharmaceutical Company Limited Controlled-release drug formulation
JP6961694B2 (ja) * 2016-07-26 2021-11-05 オージオ・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー Ｓ−エコールを用いてアルツハイマー病を診断するおよび治療する方法
US20180153859A1 (en) * 2016-12-02 2018-06-07 T3D Therapeutics, Inc. Methods of treating or preventing cognitive impairment using indane acetic acid derivatives based on apoe4 genotype
KR102142026B1 (ko) * 2017-05-31 2020-08-06 주식회사 대웅제약 방출제어가 용이한 서방성 약물 미립자의 제조방법
KR102224917B1 (ko) 2018-03-20 2021-03-09 (주)인벤티지랩 인지 장애 관련 질병의 예방 또는 치료용 약학적 조성물의 제조 방법 및 이의 제조 방법으로 제조된 인지 장애 관련 질병의 예방 또는 치료용 약학적 조성물
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2142300C (en) * 1992-10-13 2005-08-23 Allen D. Roses Methods for detecting alzheimer's disease
US6191154B1 (en) * 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
ATE476978T1 (de) * 1998-12-17 2010-08-15 Mindset Biopharmaceuticals Usa Verbesserung der geistigen fähigkeiten durch die steigerung der insulin-empfindlichkeit des gehirns
WO2005074917A1 (en) * 2004-01-30 2005-08-18 Axonyx, Inc. Methods for treatment of complications of diabetes

Also Published As

Publication number Publication date
CR9849A (es) 2008-05-21
CR9848A (es) 2008-06-18
JP2009508960A (ja) 2009-03-05
MA29872B1 (fr) 2008-10-03
PE20070618A1 (es) 2007-07-04
AR056527A1 (es) 2007-10-10
US20080262047A1 (en) 2008-10-23
MA29871B1 (fr) 2008-10-03
IL190224A0 (en) 2008-11-03
WO2007038115A2 (en) 2007-04-05
WO2007038112A3 (en) 2007-12-06
IL190217A0 (en) 2008-11-03
CA2623204A1 (en) 2007-04-05
EA200800879A1 (ru) 2008-10-30
KR20080056731A (ko) 2008-06-23
KR20080058413A (ko) 2008-06-25
TW200803896A (en) 2008-01-16
BRPI0616192A2 (pt) 2011-06-14
NO20081843L (no) 2008-06-16
TW200803851A (en) 2008-01-16
AR055649A1 (es) 2007-08-29
AU2006295007A1 (en) 2007-04-05
EP1926488A2 (en) 2008-06-04
PE20070976A1 (es) 2007-12-05
EA200800880A1 (ru) 2009-02-27
AU2006295010A1 (en) 2007-04-05
BRPI0616100A2 (pt) 2011-06-07
WO2007038112A2 (en) 2007-04-05
NO20081847L (no) 2008-06-18
EP1940403A2 (en) 2008-07-09
WO2007038115A3 (en) 2007-12-13
US20080226719A1 (en) 2008-09-18
JP2009508959A (ja) 2009-03-05

Similar Documents

Publication Publication Date Title
US20080262047A1 (en) Ppar-Gamma Agonists for Improvement of Cognitive Function in Apoe4 Negative Patients
CA2692775C (en) Methods of enhancing cognitive function using non-peptidic compounds
EP2170322B1 (en) METHODS OF MODIFYING AMYLOID ß OLIGOMERS USING NON-PEPTIDIC COMPOUNDS
US8962677B2 (en) Methods of restoring cognitive ability using non-peptidic compounds
KR20020081424A (ko) Ｐｐａｒ 매개인자의 치료학적 용도
EA025497B1 (ru) Способ лечения гиперфильтрационного поражения почек
KR20180021693A (ko) 신경퇴행성 질환을 치료하는 조성물 및 방법
US20080027052A1 (en) Methods for treating cystic kidney disease
RS67890B1 (sr) Lumateperon za upotrebu u lečenju šizofrenije
JP2025163142A (ja) Ｃｘｃｒ７アンタゴニストのｓ１ｐ１受容体調節剤との合剤
JP2024506716A (ja) 高インスリン血症の処置のためのソマトスタチン受容体５型アゴニスト
WO2010068750A2 (en) Compositons and method for treatment of mood and cognitive impairments
KR20220011651A (ko) Gapdh를 억제하기 위한 방법 및 조성물
US9006283B2 (en) Methods of modifying amyloid β oligomers using non-peptidic compounds
CN101312728A (zh) 用于改善APOE4阴性病人认知功能的PPAR-γ激动剂
US20090137626A1 (en) Pharmaceutical Composition Containing PPARgamma Agonist
EA048938B1 (ru) Комбинация антагониста cxcr7 с модулятором рецептора s1p1
JP2025524621A (ja) Ｃｙｐ３ａ誘導剤及び／又はプロトンポンプ阻害剤と組み合わせてベルモスジルを投与する方法
HK1111620A (en) Pharmaceutical composition containing ppar gamma agonist

Legal Events

Date Code Title Description
FZDE Discontinued